CRIS Current Research Information System

OTTAVIANI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.260
AS - Asia 9.870
EU - Europa 7.574
AF - Africa 618
Continente sconosciuto - Info sul continente non disponibili 520
SA - Sud America 511
OC - Oceania 16
Totale 29.369
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.047
VN - Vietnam 2.851
SG - Singapore 2.482
CN - Cina 2.475
GB - Regno Unito 2.059
SE - Svezia 1.198
IT - Italia 1.081
DE - Germania 899
HK - Hong Kong 592
FR - Francia 479
IN - India 427
RU - Federazione Russa 362
BR - Brasile 349
IE - Irlanda 267
NL - Olanda 242
KR - Corea 211
UA - Ucraina 176
ZA - Sudafrica 173
JP - Giappone 169
TG - Togo 146
FI - Finlandia 141
EE - Estonia 139
BD - Bangladesh 122
CA - Canada 117
GR - Grecia 104
NG - Nigeria 104
CH - Svizzera 101
CI - Costa d'Avorio 93
JO - Giordania 82
BG - Bulgaria 81
AR - Argentina 70
PH - Filippine 67
BE - Belgio 59
SC - Seychelles 53
IR - Iran 46
TH - Thailandia 45
AT - Austria 42
IQ - Iraq 42
PL - Polonia 42
TR - Turchia 40
ID - Indonesia 38
ES - Italia 28
MX - Messico 28
TW - Taiwan 28
UZ - Uzbekistan 28
EC - Ecuador 23
SA - Arabia Saudita 20
MY - Malesia 19
PK - Pakistan 17
PE - Perù 15
CL - Cile 13
PY - Paraguay 13
AU - Australia 12
JM - Giamaica 12
EG - Egitto 11
LB - Libano 11
RO - Romania 11
VE - Venezuela 11
CO - Colombia 10
GT - Guatemala 10
CR - Costa Rica 9
HN - Honduras 8
HR - Croazia 8
KE - Kenya 8
LT - Lituania 8
EU - Europa 7
KZ - Kazakistan 7
PT - Portogallo 7
TM - Turkmenistan 7
TT - Trinidad e Tobago 7
ET - Etiopia 6
MA - Marocco 6
MU - Mauritius 6
PR - Porto Rico 6
AE - Emirati Arabi Uniti 5
CZ - Repubblica Ceca 5
IL - Israele 5
OM - Oman 5
TN - Tunisia 5
AL - Albania 4
BB - Barbados 4
DK - Danimarca 4
MK - Macedonia 4
NI - Nicaragua 4
NP - Nepal 4
NZ - Nuova Zelanda 4
RS - Serbia 4
SI - Slovenia 4
AZ - Azerbaigian 3
CY - Cipro 3
GY - Guiana 3
KG - Kirghizistan 3
MD - Moldavia 3
PA - Panama 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
Totale 28.828
Salva come PNG Salva come JPEG
Città #
Southend 1.887
Singapore 1.725
Ashburn 1.043
Dong Ket 917
Chandler 841
Fairfield 820
San Jose 680
Hong Kong 561
Houston 467
Ho Chi Minh City 442
Wilmington 409
Beijing 402
Hefei 395
Woodbridge 388
Seattle 384
Hanoi 380
Ann Arbor 375
Santa Clara 340
Princeton 319
Cambridge 295
Dublin 266
Boardman 220
Bologna 197
Westminster 164
Seoul 163
Lauterbourg 160
Council Bluffs 159
New York 158
Padova 156
Los Angeles 155
Lomé 146
Nanjing 146
Tokyo 146
Helsinki 114
Medford 112
Milan 108
Abidjan 93
Amman 81
Bern 81
Saint Petersburg 79
Jinan 78
Sofia 78
Shenyang 77
Dallas 75
Buffalo 72
Munich 70
Abeokuta 69
Frankfurt am Main 69
Bremen 65
Haiphong 65
Hebei 62
Berlin 61
Da Nang 61
São Paulo 59
Brussels 58
Jacksonville 58
Nanchang 57
Changsha 55
Redondo Beach 55
Turin 54
San Diego 52
Shanghai 44
Tianjin 43
Florence 41
Redwood City 38
Bengaluru 37
Guangzhou 36
Rome 36
Jiaxing 35
Phoenix 35
Falls Church 34
Zhengzhou 31
Orem 30
Toronto 30
Hangzhou 29
Athens 27
Hải Dương 25
Johannesburg 25
London 25
Vienna 25
Biên Hòa 24
Xi'an 24
Falkenstein 22
Paris 22
Turku 22
Amsterdam 21
Montreal 21
Ningbo 21
Norwalk 21
Bangkok 20
Chicago 20
Taizhou 19
Warsaw 19
Chengdu 18
Mountain View 18
Taiyuan 18
Can Tho 17
Jakarta 17
Nuremberg 17
Brooklyn 16
Totale 18.347
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 358
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 355
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 347
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 346
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 308
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 304
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 290
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 279
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 279
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 279
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 266
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 261
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 257
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 253
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 253
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 250
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 243
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 240
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 237
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 235
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 232
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 232
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 230
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 229
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 226
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 224
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 222
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 220
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 217
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 213
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 212
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 210
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 206
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 205
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 205
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 204
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 204
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 204
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 203
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 202
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 202
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 196
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 196
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 195
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 194
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 193
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 193
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 192
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 191
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 191
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 189
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 189
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 187
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 186
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 186
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 185
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. 184
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 183
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 182
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 181
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 181
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 180
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 180
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 180
Clec12a: A new AML stem cell-associated antigen 179
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 178
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 176
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 176
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 176
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 175
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 175
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 173
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 173
SNP array reveals a new deletion of JAK2 in AML patients 171
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 171
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells 170
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 170
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 169
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 168
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 168
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 167
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 166
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 166
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 166
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 165
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 164
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 164
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 164
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 163
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 161
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 161
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 161
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 161
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 160
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 160
You have accessA New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 160
Totale 20.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.944
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.974 0 70 216 322 329 221 58 187 150 255 597 569
2022/20233.509 416 568 174 487 225 282 107 193 569 86 254 148
2023/2024914 35 149 39 91 49 211 61 64 59 45 63 48
2024/20253.570 137 548 292 249 459 154 331 106 35 318 164 777
2025/20268.984 746 772 720 542 940 475 789 383 2.132 827 341 317
2026/2027572 241 331 0 0 0 0 0 0 0 0 0 0
Totale 29.369